FDA
-
-
-
-
-
-
-
Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone
-
-
-
-
-
-
-
Nuwellis signs letter of intent to acquire Rendiatech monitoring firm
-
-
-
-
-
-
-
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
-
-
-
-
-
-
-
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
-
-
-
-
-
-
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas
-
-
-
-
-
322,978 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

